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Accumulating evidence reveals involvement of T lymphocytes and adaptive immunity in the chronic inflammation associated
with infectious and noninfectious diseases of the heart, including coronary artery disease, Kawasaki disease, myocarditis, dilated
cardiomyopathies, Chagas, hypertensive left ventricular (LV) hypertrophy, and nonischemic heart failure. Chemokine CXCL10 is
elevated in cardiovascular diseases, along with increased cardiac infiltration of proinflammatoryTh1 and cytotoxic T cells. CXCL10
is a chemoattractant for these T cells and polarizing factor for the proinflammatory phenotype.Thus, targeting the CXCL10 receptor
CXCR3 is a promising therapeutic approach to treating cardiac inflammation. Due to biased signaling CXCR3 also couples to anti-
inflammatory signaling and immunosuppressive regulatory T cell formationwhen activated byCXCL11. Numbers and functionality
of regulatory T cells are reduced in patients with cardiac inflammation, supporting the utility of biased agonists or biologicals to
simultaneously block the pro-inflammatory and activate the anti-inflammatory actions of CXCR3.Other immunotherapy strategies
to boost regulatory T cell actions include intravenous immunoglobulin (IVIG) therapy, adoptive transfer, immunoadsorption, and
low-dose interleukin-2/interleukin-2 antibody complexes. Pharmacological approaches include sphingosine 1-phosphate receptor
1 agonists and vitamin D supplementation. A combined strategy of switching CXCR3 signaling from pro- to anti-inflammatory and
improving Treg functionality is predicted to synergistically lessen adverse cardiac remodeling.
1. Introduction
The chemokine receptor CXCR3 is a Class A seven-
transmembrane-domain or G protein-coupled receptor
(GPCR) that is involved primarily in chemotaxis of certain
immune cells, inhibition of angiogenesis, and Th1 cell
polarization [1–3]. CXCR3 is expressed by various effector T
lymphocytes, including CD4+ T helper 1 (Th1) cells, CD8+
cytotoxic T lymphocytes (CTL), and CD4+ and CD8+ mem-
ory T cells, as well as monocytes, M1 macrophages, natural
killer (NK) cells, subsets of B-cells, mast cells, endothelial
cells, and vascular smoothmuscle cells [1–4]. CXCR3 couples
to G𝛼i protein [5, 6] and although not extensively studied, it
has been shown to activate a number of signaling pathways
that are generally associated with GPCRs such as increases
in intracellular calcium and activation of MAP kinases and
PI3K/Akt signaling [4, 7, 8].The principal agonists of CXCR3
are CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC).
The human equivalent of the murine form of CXCR3 is
CXCR3A and unless noted otherwise CXCR3 is used in
this review to include both murine and human isoforms.
Two additional splice variants of CXCR3 are expressed in
humans, CXCR3B and CXCR3-alt. CXCR3B, which couples
to Gs, is the receptor isoform expressed in microvascular
endothelial cells and is linked to inhibition of angiogenesis
and induction of apoptosis [2, 3]. Besides CXCL9, CXCL10,
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and CXCL11, CXCR3B and CXCR3 are activated by CXCL4
and CXCL4L1, chemokines that are released by platelets and
have been implicated in atherogenesis and acute coronary
syndrome [3, 9, 10]. CXCR3-alt is a truncated form of CXCR3
that is selectively activated by CXCL11 [2–4].
CXCR3 is associated with the pathophysiology of Th1-
type diseases, including infections of various etiologies and
autoimmune disorders [1, 3]. Although CXCR3 is activated
by CXCL9, CXCL10, and CXCL11, the outcome is different
with growing evidence that CXCL9 and CXCL10 are essen-
tially proinflammatory, while CXCL11 has anti-inflammatory
actions [11, 12]. Over the last decade, numerous studies
have documented elevated circulating levels of CXCL10 in
wide-ranging infectious and autoimmune diseases, autoim-
mune encephalomyelitis, Crohn’s disease, tuberculosis, thy-
roid autoimmune diseases, and type 1 diabetes, as well as
several cancers [13–18]. Recent evidence from us and others
[1] has revealed the importance of theCXCL10/CXCR3 axis in
cardiovascular diseases. As discussed elsewhere [11], CXCL9
and CXCL10 are two of only 8–10 chemokines that are
sufficient to sustain an inflammatory response. In addition,
the homing signature for memory T cells to the heart from
mediastinal lymph nodes is c-Met+CCR4+CXCR3+. While
c-Met triggering supports cardiotropic T cell recirculation,
CXCR3 and CCR4 engagement via tissue-released CXCL10
and CCL4, respectively, sustains recruitment in heart inflam-
mation [19, 20]. In this review, we present an overview of the
role of CXCL9 and CXCL10 in infectious and noninfectious
diseases of the heart and its implications for immunotherapy.
2. CXCR3 Biased Signaling
Recently, Zohar et al. [21] showed that CXCL9 and CXCL10
drive effector Th1/Th17 cell polarization via STAT1, STAT4,
and STAT5 activation, thereby promoting inflammation. In
contrast, CXCL11, which exhibits relatively higher binding
affinity for CXCR3, drives development of FOXP3 (forkhead
box P3)-negative IL-10high T regulatory 1 (Tr1) cells and IL-4hi
Th2 cells via STAT3 and STAT6 activation and was demon-
strated to dampen inflammation [21]. The opposite actions
of the CXCR3 agonists are likely the consequence of the
biased signaling that is a fixture of GPCRs, which can activate
both G protein-dependent and protein-independent signal-
ing cascades, the latter occurring via 𝛽-arrestin 2 recruitment
[1, 11, 12]. Biased allosteric agonists of CXCR3 that selectively
activate 𝛽-arrestin or G protein-dependent signaling are in
development and may have utility in immunotherapy [22].
3. Coronary Artery Disease
(Ischemic Heart Disease)
Coronary artery disease (CAD), which progresses to coro-
nary heart disease, is a leading cause of death in the USA
and globally [23, 24]. CAD is caused by atherosclerosis within
the arteries of the heart, a chronic inflammatory condition
associated with waxy plaque buildup [25]. CXCR3 expressing
monocytes/macrophages, Th1 cells, NK cells, and CTL cells
play a critical role in atheromatous plaque progression and
eventual disruption [1]. Ruptured or ulcerated plaques cause
formation of a thrombus that precipitates an acute coronary
syndrome, such as unstable angina or a heart attack.
Endothelial dysfunction, increased vascular permeability,
increased expression of adhesion molecules on endothelial
cells for leukocytes, and increased plasma levels of lowdensity
lipoprotein (LDL) are initiating factors in atherosclerosis [1].
LDL, which accumulates in the intima, undergoes oxida-
tion by macrophages and endothelial cells, as well as by
VSMC that migrate into the intima from the media and
proliferate. In response to the oxidized LDL and plasma
LDL, endothelial cells secrete proinflammatory cytokines and
chemokines (MCP-1/CCL2, fractalkine, and CXCR3 ligands)
that attractmonocytes, which differentiate into dendritic cells
or macrophages that accumulate oxidized LDL to become
foam cells. T cells are recruited into the intima, and dendritic
and NK cells help induce the CD4+Th1 phenotype, which is
the most abundant T cell population in human atheroscle-
rotic plaques [26]. CXCR3 is required for optimal Th1 gener-
ation [27]. Th1 cells, as do NK cells, produce IFN-𝛾, which
contributes to Th1 polarization, activates proinflammatory
M1 macrophages, and induces apoptosis. The atheromatous
plaque that builds up in the artery wall is made up of an accu-
mulation of lipids, fibrous connective tissue, macrophages,
and cellular debris that arises from the cytolytic actions of oxi-
dized LDL, NK cells, IFN-𝛾, and CTL cells on macrophages,
foam cells, VSMC, and endothelial cells. A fibrous coat of
extracellular matrix proteins produced by VSMC stabilizes
the plaque, but proinflammatory M1 macrophages secrete
metalloproteinases in response to IFN-𝛾 that degrade the
fibrous cap and enhance its vulnerability to rupture.
CXCL10 is reported to be expressed by endothelial cells,
smooth muscle cells, and macrophages during the formation
of atherosclerotic lesions in both preclinical and clinical
studies [28, 29]. Suppression of CXCL10 bioactivity in Apo-
E deficient mice resulted in a more stable plaque phenotype
with less macrophage activation, along with more smooth
muscle cells and collagen abundance [30]. The mechanistic
role of CXCL10 in the pathogenesis of atherosclerotic plaque
growth and destabilization is not yet resolved. Of note,
CXCL10 concentrations increase in patients with a more
vulnerable plaque phenotype [30]. Unstable plaques have
increased levels of Th1, NK, and CTL cells and decreased
levels of anti-inflammatory regulatory T (Treg) cells [31].
Recent studies show that the relative levels of Treg cells are
reduced and their functionality is impaired in patients with
CAD [32, 33]. Knockout of CXCL10 in the apolipoprotein
E-deficient mouse model of atherosclerosis was associated
with increased Treg cell numbers and activity, along with a
reduction in lesion formation [34].
Circulating levels of CXCL10 are elevated in patients
with coronary artery disease [35, 36]. Notably, CXCL10 was
also reported to be produced by the endothelium of mouse
coronary blood vessels infused with angiotensin II [37],
human coronary artery endothelial cells treated with TNF-𝛼
[38], and rat cardiacmicrovascular endothelial cells subjected
to hypoxia/ischemia [39]. Patients with acute myocardial
infarction (AMI) showed significantly higher serum levels
of CXCL10 than control subjects and patients with stable
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angina pectoris [40]. Although serum CXCL10 levels were
negatively correlatedwith infarct size, these results in terms of
pathogenic implications and determining cause versus effect
relationships have limitations. First, during AMI there is
a massive systemic inflammatory insult in which CXCL10
levels are expected to be high. It would be interesting to test
blood concentration of CXCL10 within the first 3 hours after
angina onset during AMI when systemic activation is not
yet started. Secondly, the pathogenic mechanisms of plaque
rupturemay involve factors acting locally without necessarily
showing a high systemic blood concentration. It would be
interesting to analyze CXCL10 in samples of blood obtained
by thrombus-aspiration during coronary artery percutaneous
intervention (PCI) in patients with unstable coronary artery
disease. In patients with first-time ST-segment elevation
AMI, high circulating levels of CCL4, CXCL16, CXCL8, and
CXCL10 within the first week after PCI were found to be pos-
itively correlated with the degree of myocardial damage [41].
4. Kawasaki Disease
Kawasaki disease is an autoimmune disease that manifests
as a systemic vasculitis with a predilection for coronary
arteries [42]. The disease occurs in children under 5 years
of age and a preexisting viral infection may have a role in
its development. During the acute phase of Kawasaki disease
the immune system is highly activated and includes bothTh1
and Th2 subsets [43]. Recently, Ko et al. [44] reported that
CXCL10 is a good biomarker/predictor of Kawasaki disease
and, furthermore, that CXCR3 is activated in the T cells of
patients with acute Kawasaki disease. In addition, several
studies report that numbers and functionality of Treg cells are
reduced in Kawasaki patients [45–48].
5. Myocarditis and Chagas Heart Disease
Myocarditis or inflammation of the myocardium is a hetero-
geneous group of disorders initiated by various pathogens,
including worms, bacteria, protozoa, rickettsia, and most
commonly viruses [49]. Myocarditis may lead to heart failure
and sudden death. Autoimmunity after viral myocarditis is
thought to cause dilated cardiomyopathy, which is charac-
terized by ventricular dilation and contractile dysfunction
[50, 51].
CXCL10 is elevated in the heart following viral and
nonviral infection and has the characteristics of a biomarker
in rodent models of myocarditis [52, 53]. Yue et al. [54]
reported findings showing that CXCL10 contributes to the
pathogenesis of viral myocarditis. In their study, myocarditis
was induced with Coxsackievirus B3 (CVB3), the primary
cause of viral myocarditis, in mice that overexpressed a
CXCL10 mutant protein without functional activity in order
to antagonize endogenous CXCL10. These mice exhibited
ameliorated disease progression, including reduced cardiac
thickening (due to inflammatory edema), inflammation, and
cell death, as well as improved survival when compared to
wild-type mice [54]. The authors concluded that CXCL10
plays a crucial role in recruitment of Th1 cells to the heart,
leading to the increase in detrimental proinflammatory Th1
cytokines. These findings have implications for interferon
treatment, which is beneficial for some forms of viral
myocarditis [55]. Following CVB3 infection, the rise in IFN-𝛾
stimulates CXCL10 expression in cardiac myocytes and other
cardiac cells. Yuan et al. [56] reported that CXCL10 inhibits
CVB3 replication at early stage of infection, consequently
protecting cardiac myocytes from damage and improving
heart function. This antiviral activity of CXCL10 entails
the regulation of natural killer (NK) cell infiltration into
the myocardium and associated IFN-𝛾 expression. However,
the transient antiviral effect of CXCL10 was shown to be
insufficient for viral clearance and in preventing death during
acute inflammation stages in their mouse model. Other
chemokines or cytokines were proposed to play an important
role in clearance of viruses. No simple explanation seems to
explain the disparate findings of Yuan et al. [56] and Yue et al.
[54] on whether myocardial CXCL10 is harmful or beneficial
in the context of acute CVB3 myocarditis, although timing
and dosage levels of CXCL10 and effective viral clearance
versusTh1 recruitment are likely contributing factors.
Evidence indicates the major contribution of autoim-
munity to the etiology of myocarditis and thus adoptive
transfer of Tregs and/or stimulating their differentiation are
promising therapeutic approaches [49, 50]. Another possible
immunotherapy approach is humanized monoclonal anti-
bodies targeting IL-17 derived fromTh17 cells [49]. BothTh1
and Th17 cells drive myocarditis, with Th17 cells playing an
important part in the development of dilated cardiomyopathy
[57].
Chagas disease is a tropical disease that results from
infection with the protozoan parasite Trypanosoma cruzi
and affects ∼10 million individuals worldwide but is most
prevalent in Latin America [58, 59]. In some, 20–30%, of
infected individuals, chronic infection leads to a potentially
fatal cardiomyopathy known as Chagas heart disease, gen-
erally 10–20 years after the initial infection [60, 61]. Chagas
heart disease is characterized by marked inflammation and
fibrosis of the heart, along with cardiac edema, myofibril-
lar destruction, chamber dilation, and loss of contractile
function. The etiology of Chagas heart disease is not fully
understood and likely multifactorial, with a contribution of
an autoimmune response due in part to molecular mimicry
between antigenic determinants of T. cruzi and human (car-
diac) antigens [62, 63]. With heart failure in Chagas disease,
myocardial levels of CD8+ and CD4+ T cells are increased,
with a predominance of CD8+ T cells [61, 64, 65]. In addition,
the myocardium exhibits a strong Th1 cytokine profile with
increased expression of IFN-𝛾 and IL-18 genes that correlate
with ventricular dilation [64, 65]. Circulating levels of IFN-
𝛾 are elevated during chronic Chagas disease [61] and were
reported to be inversely correlated to left ventricular ejection
fraction (LVEF) [66]. In contrast, Chagas-related heart failure
is associated with reduced myocardial levels of Treg cells
[61, 64], and circulating Treg activity was reported to be
reduced in moderate or severe cardiomyopathy with activity
directly correlated to LVEF [66].
Several studies have implicated CXCL10 in Chagas
cardiomyopathy. Increased plasma levels of CXCL10 were
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detected in patients with chronic Chagas disease [67], and LV
mRNA expression levels ofCXCL10were found to be elevated
in patients with Chagas cardiomyopathy [68]. Recently,
evidence was provided that polymorphisms in the CXCL9
and CXCL10 genes controlled the expression of chemokines
in the myocardium and the degree of myocarditis in Chagas
cardiomyopathy [69].
Behc¸et’s disease is an autoimmune or autoinflammatory
disorder common in the Middle East, Asia, and Japan.
The basis for the pathogenesis of Behc¸et’s disease is not
known, although a number of factors have been proposed
to have a role, including viral, bacterial, environmental,
genetic, and immune factors. Behc¸et’s is caused by small-
vessel systemic vasculitis that very often affects the heart in
diverse ways, including endomyocardial fibrosis, intracardiac
thrombus, endocarditis, pericarditis, myocarditis, coronary
arteritis, myocardial infarction, and valvular disease [70].The
cardiomyopathy may be ischemic, nonischemic, or inflam-
matory in nature and may manifest as asymptomatic systolic
or diastolic dysfunction or overt systolic or diastolic heart
failure [70]. Recently, monocytes of Behc¸et’s patients were
found to have dysfunctional posttranscriptional regulation of
CXCL10 mRNA that resulted in overexpression of CXCL10
protein with IFN-𝛾 stimulation [70]. Thus, overexpression of
CXCL10 may contribute to the pathogenesis of Behc¸et’s dis-
ease. In general, the role of CXCL10 in immune-mediated and
autoimmune myocarditis is little studied; however, based on
studies of infective myocarditis, a critical role for CXCL10 is
likely.The role of CXCL10 in cardiac allograft transplantation
rejection is discussed elsewhere [1].
6. LV Hypertrophy and Nonischemic
Heart Failure
After CAD, hypertension is the most common risk factor for
heart failure and accounts for ∼25% of heart failure cases
[71]. In the elderly, as many as 68% of heart failure cases
are linked to hypertension and community-based studies
indicate that hypertension contributes to heart failure in
60% of patients [72]. Hypertension causes a number of
adverse remodeling events at the cellular and tissue level of
the heart, including cardiac myocyte hypertrophy and gene
reprograming, activation of cardiac fibroblasts, interstitial
and perivascular fibrosis, and capillary refraction [73–75].
These alterations ultimately cause marked changes in the
overall geometry of the heart that may progress to heart
failure and the inability of the heart to adequately meet the
oxygen and energy demands of the body. Heart failure (HF)
may manifest clinically with either preserved or reduced
LVEF, which are designated HFpEF (so-called diastolic heart
failure) and HFrEF (systolic heart failure), respectively [75].
Hypertension results in concentric LV hypertrophy,
which may progress to ventricular dilation and eventual
HFrEF because of poorly understoodmeans thatmay include
ischemic injury [76, 77]. Related to this, volume overload
due to fluid retention and impaired kidney function may
cause a dilated pattern of eccentric LV hypertrophy with
hypertension that leads to HFrEF [77]. Generally, cardiac
remodeling with hypertension reflects a combination of
both concentric and eccentric patterns of remodeling [77].
Concentric hypertrophy is also a characteristic of HFpEF,
which typically has hypertension as the major comorbidity
[78]. In addition, microvascular dysfunction concomitant to
hypertension is thought to be a contributing factor forHFpEF
[79].The relative importance of CXCL10 in concentric versus
eccentric LV hypertrophy, as well as their progression to heart
failure, is not known.
Numerous preclinical and clinical studies have implicated
marked activation of neurohormonal drive to the heart in the
pathoetiology of LV hypertrophy and its progression to heart
failure [80]. Neurohormonal drive, namely, activation of the
sympathetic and renin-angiotensin-aldosterone systems, is
generally thought to directly cause adverse remodeling of the
heart. At the same time, there is evidence for indirect actions
of neurohormonal stimulation on cardiac remodeling via
activation of innate immunity and inflammation, especially
the induction of heart-derived proinflammatory cytokines
[81]. In chronic heart failure, an increased Th1/Th2 ratio is
seen [82], but whether increased Th1 cell levels contribute to
heart failure progression or simply are a consequence of heart
failure is unresolved.
Exciting new findings have now implicated adaptive
immunity and T cells more directly as causal agents in hyper-
tensive LV hypertrophy and resultant heart failure by poorly
understood means. These preclinical studies employed the
mouse model of transverse aortic constriction- (TAC-)
induced heart failure to mimic the impact of high blood
pressure on the heart. We observed that circulating levels
of CXCL9 and CXCL10 are elevated in TAC mice [83].
Laroumanie et al. [84] reported increased recruitment of
activated CD4+ and CD8+ T cells and elevated levels of
several chemokines for T cells and monocytes, including
CXCL10, in ventricular tissues from mice with TAC-induced
heart failure. TAC-induced ventricular dilation and fibrosis
was prevented and contractile dysfunction was attenuated
in mice deficient in mature B and T lymphocytes due to
knockout of RAG2, although cardiac hypertrophy was still
observed. T cell replenishment in RAG2 knockout mice
restored the TAC-induced heart failure phenotype. In addi-
tion, elimination of CD4+ T cells (MHCII knockout) but
not CD8+ T cells (CD8+ knockout) prevented TAC-induced
cardiac fibrosis and failure, suggesting a critical involvement
of T helper cells. This conclusion was further supported by
the observation that mice with transgenic T cell receptor
specific for ovalbumin did not develop heart failure and
fibrosis with TAC. Altogether these findings suggest that
activation of CD4+ T cells in hypertension causes interstitial
and perivascular fibrosis that leads to functional and mor-
phological changes in the heart conducive to the development
of heart failure. However, it should be noted that an earlier
study reported that coronary vessels of RAG1 knockout mice
exhibited more intimal hyperplasia and perivascular fibrosis
compared to wild-type mice following TAC [85]. The basis
for the discrepant findings of the two studies is not clear.
More recently, Nevers et al. [86] also investigated the role of
T cells in cardiac remodeling in response to TAC-induced
pressure overload. They observed that the development of
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systolic dysfunction was associated with the kinetics of T cell
infiltration into the left ventricle and evidence was provided
that most of the infiltrating T cells were IFN-𝛾 secreting
Th1 cells. LV systolic and diastolic function were preserved
with TAC in T cell deficient mice (T cell receptor (TCR)
knockout), and LV hypertrophy, fibrosis, and inflammation
were markedly attenuated. In addition, T cell depletion with
an anti-CD3 antibody prevented heart failure in wild-type
mice. Unresolved at present is the identity of the antigen(s)
responsible for T cell activation in LV hypertrophy and heart
failure, and the potential contribution played by the loss of
regulatory mechanisms that normally protect the heart from
T cells [87].
In contrast to the involvement of adaptive immunity in
TAC, Ma et al. [88] provided evidence that CD8+ T cells
play a critical role in perivascular and interstitial fibrosis
in the angiotensin II infusion model of hypertensive car-
diac remodeling through the recruitment and activation of
macrophages. They found that CD8+ T cells are recruited
to the heart and activated by IFN-𝛾 secreting myocardial
cells; recruited macrophages in turn are activated by CD8+ T
cells in contact-dependent, but TCR-independent means. A
possible contribution of CD4+ T cells to the actions of CD8+
T cells will need to be explored.
Circulating levels of CXCL10 are elevated in patients with
untreated essential hypertension [89]. In a small cohort, we
observed that the CXCR3 chemokines, including CXCL10,
were present in elevated concentrations in the plasma of
patients with symptomatic diastolic LV dysfunction indica-
tive of HFpEF or early stage HFrEF [90]. The magnitude of
their increase was independent of the extent of hypertension
and the CXCR3 agonists enhanced diagnostic accuracy over
and beyond NT-pro BNP. More recently, we reported that
circulating CXCL10, MIP-1𝛼, and CD40 ligand were the best
indicators for differentiating healthy and heart failure sub-
jects [91].We found that serumCXCL10 levels were increased
in patients with symptomatic heart failure as indexed by
NYHA classification II through IV and were positively cor-
related with serum levels of Th1 proinflammatory cytokines.
The findings of these two studies are consistent with the idea
that inflammation is involved in the pathogenesis of heart
failure with CXCL10 playing a central role.
Numerous preclinical studies and recent genome-wide
association studies (GWAS) support a role for both cytotoxic
(CD8+) T cells and Th (CD4+) lymphocytes in human
hypertension [92, 93]. However, accumulating evidence from
experimental studies indicates that increasing Treg cell levels
in hypertension is an effective strategy to preserve cardiac
function, attenuate cardiac hypertrophy and fibrosis, and
prevent heart failure progression, independent of any blood
pressure lowering effects [94–96]. Reduced circulating levels
of Treg cells in heart failure patients have been reported in
several studies [97–99].
The role of CXCL10 in other forms of nonischemic
heart failure with reduced ejection fraction, such as restric-
tive cardiomyopathy, ion channelopathies, and diabetic car-
diomyopathy, awaits investigation. Recently, Di Luigi et al.
[100] reported that the phosphodiesterase type 5 inhibitor
sildenafil decreased elevated circulating CXCL10 levels in
subjects with diabetic cardiomyopathy, suggesting that silde-
nafil could be used pharmacologically to mitigate CXCL10-
associated inflammation in diabetic cardiomyopathy. Recent
findings support a role for CXCL10 in right ventricular
(RV) remodeling as well. Waehre et al. [101] found that
several chemokines, most notably CXCL10, are upregulated
in the pressure-overloaded right ventricle and play a role
in myocardial extracellular matrix remodeling in an animal
model of pulmonary stenosis. CXCL10 is implicated also in
RV dysfunction and inflammation following experimental
pulmonary embolism in rats [102].
7. Implications for Immunotherapy
The chemokine receptor CXCR3 and its agonist CXCL10 are
potential drug targets to treat various cardiovascular diseases.
Potential immunotherapies for cardiac inflammation are
as follows:
Treg Stimulation
(i) IL-2/anti-IL-2 complex treatment to enhance Treg
number and activity
(ii) Targeted cytokine-infused nanoparticles to stabilize
and expand Tregs in vivo
(iii) Intravenous immunoglobulin (IVIG) therapy to
boost Treg activity
(iv) Vitamin D to modulate formation and activity of
Tregs
(v) Atorvastatin to enhance Treg number and activity
(vi) FTY720 to increase Treg levels and activity
(vii) Adoptive Treg cell transfer
Immunosuppression
(i) Immunoadsorption to remove circulating antibodies
and boost Treg activity
(ii) Phosphodiesterase type 5 inhibitor to decrease
CXCL10 formation
(iii) CXCL11 to stimulate biased GPCR anti-inflammatory
signaling
(iv) PPAR-𝛾 agonists to block CXCL9, CXCL10, and
CXCL11 formation
Levels of CXCL10 are generally elevated with chronic car-
diac inflammation, which is associated with enhanced Th1
polarization and infiltration into the myocardium. CXCR3
plays a key role in recruiting various leukocytes to the heart,
including monocytes, effector lymphocytes, and CTL cells
[1]. Peroxisome proliferator-activated receptor- (PPAR-) 𝛾
agonists may be a potential pharmacological treatment to
block CXCL9, CXCL10, and CXCL11 formation in patients,
as PPAR-𝛾 agonists show a strong inhibitory effect on their
expression and production in vitro [103]. Pioglitazone, which
lacks the adverse cardiovascular effects of older thiazolidine-
diones andmay be cardiovascular protective, looks promising
in this regard, although pioglitazone is contraindicated in
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CAD 1; 27; 31; 32 32–34 35–37
Kawasaki 44 45 46–49
Myocarditis/Chagas 58; 62; 65;66 62; 65; 67 68; 69; 71
Hypertrophy 83; 84; 86;92; 93 97–99 84; 89–91
heart failure patients likely due to fluid retention [104–
107]. Another potential therapeutic approach is the phos-
phodiesterase type 5 inhibitor sildenafil, which was recently
reported to decrease CXCL10 gene expression and protein
secretion in human cardiac myocytes and decrease circulat-
ing CXCL10 in subjects with diabetic cardiomyopathy [100].
There is substantial evidence that sildenafil has protective
effects against adverse remodeling of the heart [108].
Although CXCL9, CXCL10, and CXCL11 all bind to
CXCR3, there is evidence that these agonists activate oppos-
ing responses due to biased signaling that is a fixture of
G protein-coupled receptors [1, 11, 12]. Whereas CXCL9/
CXCL10/CXCR3 interactions drive effector Th1 polarization,
CXCL11/CXCR3 binding seems to induce an immunotoler-
ant state characterized by T lymphocyte polarization into
regulatory Tr1 lymphocytes that produce anti-inflammatory
IL-10 [11, 12]. Therefore, inhibiting CXCR3 may not yield
definitive findings. Biased agonists have been developed that
exert CXCL11-like actions at CXCR3 [22] but have not as
yet been assessed in experimental models of cardiovascular
diseases. An alternative approach might involve a biological
compound. CXCL11 has a short half-life in vivo. To address
this shortcoming, Zohar et al. [21] generated a stabilized form
of CXCL11 by creating a fusion protein in which CXCL11 was
linked to IgG1. When administered during ongoing autoim-
mune encephalomyelitis, the fusion protein suppressed the
disease by increasing the number of IL-10-secreting Tr1-like
cells (direct effect) and reducingTh1 polarization.
Targeting CXCR3 might be more effective in treating
chronic heart inflammation in combination with approaches
to enhance Treg numbers or activity, which are generally
reduced in cardiovascular diseases (Table 1). Regulatory T
cells are immunosuppressive and anti-inflammatory, and a
growing number of experimental studies have shown their
beneficial effects on the heart in various experimental models
of coronary artery disease [109, 110], Kawasaki disease [111],
myocarditis and dilated cardiomyopathies [112–117], Chagas
heart disease [118, 119], hypertensive LV hypertrophy [95, 96],
and nonischemic heart failure [94, 109, 120]. Although not
discussed here, boosting Treg numbers or activity in the
heart is reported to be beneficial as well in experimental
models of infarction-driven remodeling [121–124]. Increasing
levels of IL-10-secreting Treg/Tr1 cells may be particularly
advantageous, as IL-10 has anti-inflammatory and protective
actions on the vasculature and heart [125–132]. Intravenous
immunoglobulin (IVIG) therapy has been shown to be effec-
tive in treating acuteKawasaki disease in 80–90%ofKawasaki
patients with rapid resolution of clinical symptoms and
reduced risk of coronary disease [133]. Although the exact
basis for the effectiveness of IVIG therapy is not clear, IVIG
therapy is thought to modulate the inflammatory process
and recent evidence indicates that IVIG therapy acts in part
by stimulating an immature myeloid population of dendritic
cells that secretes IL-10 and favors expansion of Fc-specific
natural Treg cells [134]. IVIG may have promise for treating
viral myocarditis [55] and might be effective in treating
Chagas [135], as well as chronic heart failure, including both
ischemic and idiopathic dilated cardiomyopathies [136].
Adoptive transfer of Tregs and/or stimulating their dif-
ferentiation are promising therapeutic approaches to target
cardiac inflammation [49, 50], although the concerns that
must be overcome to make adaptive transfer routine therapy
in humans are considerable [137]. However, the safety and
efficacy of Treg immunotherapy in humans is supported
by preliminary clinical trials for treating graft versus host
disease [137, 138]. Immunoadsorption, which is a promising
approach for treating myocarditis and dilated cardiomyopa-
thy, may have beneficial effects by not merely removing
circulating antibodies, but increasing Treg activity [49, 139–
141].
It may be feasible to selectively enhance Treg numbers
using a pharmacological approach. The prodrug FTY720
(Fingolimod) is phosphorylated in vivo and has been shown
to trap na¨ıve and memory T cells in the thymus and
secondary lymphoid organs by downregulating sphingosine
1-phosphate receptor 1 (S1P1) [142]. Activation of S1P1 is
linked to inhibition of Treg cell differentiation [142]; however,
FTY720 and phosphorylated FTY720 increase Treg levels and
activity in vivo and in vitro [143–146]. The exact mechanism
is unclear but may require higher doses [144]. The inhibitory
effects of atorvastatin on inflammation in acute coronary
syndrome (ACS)may be due to its beneficial effects onnatural
Tregs [147]. In patients with ACS, atorvastatin treatment
increased the percentage and inhibitory ability of natural
Tregs.
IL-2 plays a critical role in Treg cell activity, growth,
and survival, but there may be insufficient IL-2 to sustain
their in vivo potentiation [12]. Emerging evidence indicates
that enhancing Treg cell numbers and activity with low-
dose IL-2 treatment is effective in treating autoimmune and
inflammatory diseases [12, 148–151], although there may be
intrinsic risk as IL-2 is also a key growth factor for effector
CD4+ T cells and NK cells [12]. An IL-2/anti-IL-2 immune
complex is reported to preferentially expand Treg cells with
little or no effect on other cells [121]. Delivery of the complex
to mice before TAC was recently reported to attenuate
LV hypertrophy, inflammation, and contractile dysfunction,
while increasing LV levels of Treg cells [94]. Inert biodegrad-
able nanoparticles represent another promising platform for
stabilizing and expanding Tregs in vivo. McHugh et al. [152]
recently reported success in using nanoparticles loaded with
the Treg inducers IL-2 and TGF-𝛽 and targeted to CD4+ T
cells with conjugated antibodies. These nanoparticles were
demonstrated to induce CD4+ Tregs in vitro, even in the
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presence of proinflammatory cytokines, and expand their
number in mice in vivo.
Vitamin D status has been linked to chronic heart failure
and vitamin D supplementation improves LV structure and
function in heart failure patients [153]. Recent evidence
indicates a modulatory role of the vitamin D system in the
formation and activity of regulatory T cells [154]. Vitamin
D deficiency was associated with reduced numbers and
impaired function of na¨ıve CD45RA+ regulatory T cell in
chronic heart failure patients [120]. In addition, the vitamin
D receptor agonist BXL-01-0029 was shown to inhibit IFN-
𝛾 and TNF-𝛼-induced CXCL10 secretion by fetal human
cardiac myocytes and reduce CXCL10 protein secretion and
gene expression by CD4+ T cells [155]. Whether a vitamin D
receptor agonist or supplementation increases Treg levels and
reduces CXCL10 levels in heart failure patients will need to be
assessed.
8. Conclusions and Future Perspectives
The last decade has witnessed an impressive advance in
our understanding of the role of the immune system in
the pathophysiology of cardiovascular diseases. Beyond an
expected role in allograft disease and the development and
progression of atherosclerosis, an abundant body of evidence
supports a significant contribution of the immune system
to many other cardiovascular settings, ranging from the
development and maintenance of hypertension to cardiac
and vessel remodeling (whether constrictive or expansive) in
response to hemodynamic stress [156], in both health and
disease. The challenge now is to translate this knowledge
for the benefit of patients suffering from cardiovascular
diseases. Targeting the CXCL10/CXCR3 axis and cardiac
inflammation may open new pharmacological venues for
treating heart failure or coronary artery disease to supple-
ment current drugs that target the sympathetic or renin-
angiotensin systems, or platelets. This will require selectively
targeting the most critical immune pathways in order to
optimize interference with pathological processes, while
preserving protective and homeostatic immune functions.
Antigen-specific modulation of the immune system, for
example, through systemic delivery of nanoparticles coated
with disease-relevant peptides bound to major histocompat-
ibility complex class II (pMHCII) to expand endogenous
antigen-specific Tregs [157], is an optimal strategy in settings
where an antigen-specific adaptive immune response has
been involved in disease development or progression. How-
ever, several cardiovascular diseases will probably resist the
identification of a specific pathogenic antigen andwill require
a broader, although targeted, regulation of the immune
response, for example, through administration of low-dose
IL-2 to promote endogenous Tregs [149]. With regard to
CXCR3 pathway, besides the therapeutic possibilities listed
above, we believe that the identification and development of
selective Evasins [158] or Evasin-like peptides that differen-
tially bind and neutralize CXCL9 or CXCL10 versus CXCL11
may provide an interesting therapeutic strategy to limit
pathogenic while preserving regulatory CXCR3 functions.
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